A.R.T. Advisors’s AMAG Pharmaceuticals AMAG Stock Holding History

A.R.T. Advisors’s Portfolio AMAG Stock Details AMAG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-10,080	Closed	-$101K	–	1866
2019 Q2	$101K	Buy	+10,080	New	+$109K	0.01%	1193
2017 Q3	–	Sell	-24,306	Closed	-$447K	–	1816
2017 Q2	$447K	Sell	24,306 -221,594	-90%	-$4.39M	0.02%	847
2017 Q1	$5.54M	Buy	245,900 +205,000	+501%	+$4.91M	0.26%	85
2016 Q4	$1.42M	Buy	+40,900	New	+$1.22M	0.08%	371
2015 Q3	–	Sell	-178,387	Closed	-$12.3M	–	1714
2015 Q2	$12.3M	Buy	178,387 +28,969	+19%	+$1.82M	0.41%	18
2015 Q1	$8.17M	Sell	149,418 -21,822	-13%	-$1.04M	0.28%	71
2014 Q4	$7.3M	Buy	171,240 +114,508	+202%	+$4.14M	0.27%	65
2014 Q3	$1.81M	Buy	+56,732	New	+$1.21M	0.08%	325
2014 Q2	–	Sell	-55,142	Closed	-$1.07M	–	1628
2014 Q1	$1.07M	Buy	55,142 +26,461	+92%	+$562K	0.06%	475
2013 Q4	$696K	Buy	28,681 +4,504	+19%	+$106K	0.04%	639
2013 Q3	$519K	Sell	24,177 -20,784	-46%	-$491K	0.03%	756
2013 Q2	$1M	Buy	+44,961	New	+$991K	0.03%	626

Other funds holding AMAG

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

A.R.T. Advisors's AMAG Position: Q3 2019 in Review

A.R.T. Advisors sold out of AMAG Pharmaceuticals (AMAG) in Q3 2019, closing a stake of 10,080 shares — an estimated $101K sold.

A.R.T. Advisors first reported a position in AMAG in Q2 2013 and held it in 12 quarters. The position peaked at $12.3M in Q2 2015. 156 funds tracked by Wall St. Rank hold AMAG as of Q3 2019.

A.R.T. Advisors reported no remaining AMAG Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
A.R.T. Advisors sold 10,080 AMAG Pharmaceuticals shares in Q3 2019, an estimated $101K.
A.R.T. Advisors first reported a position in AMAG Pharmaceuticals in Q2 2013 and held it in 12 quarters.
A.R.T. Advisors's AMAG Pharmaceuticals position peaked at $12.3M in Q2 2015.
156 funds tracked by Wall St. Rank held AMAG Pharmaceuticals as of Q3 2019.

Based on A.R.T. Advisors's 13F filing for Q3 2019, filed 14 Nov 2019.